

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	10/777,488
	Filing Date	February 12, 2004
	First Named Inventor	Adnan M.M. Mjalli
	Art Unit	1614
	Examiner Name	Unknown
Total Number of Pages in This Submission	Attorney Docket Number	TTP 2002-08

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Express Mail Certificate; Information Disclosure Statement; PTO/SB/08A; and Return Postcard
<b>Remarks</b>		


SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm			
Signature			
Printed Name	Samuel B. Rollins		
Date	Nov. 30, 2004	Reg. No.	52,180

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Signature			
Typed or printed name		Date	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 507590141 US



## EXPRESS MAIL CERTIFICATE

"Express Mail" Label No. : EV 507590141 US

Serial No. : 10/777,488

Applicant(s) : Adnan M.M. Mjalli et al.

Filing Date : February 12, 2004


Title: : SUBSTITUTED AZOLE DERIVATIVES AS  
THERAPEUTIC AGENTS

Examiner : Unknown

Group Art Unit : 1614

Type of Document(s) : Express Mail Certificate;  
Transmittal Form;  
Information Disclosure Statement;  
PTO/SB/08A Forms; and  
Return Postcard

I hereby certify that the documents identified above are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated below and are addressed to Mail Stop Amendment, Commissioner for Patents, P O Box 1450, Alexandria, VA 22313-1450.

 (signature)  
Christine Heerschap

Date Mailed:

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**



Applicant : Adnan M.M. Mjalli et al.  
Ser. No. : 10/777,488  
Filing Date : February 12, 2004  
For : SUBSTITUTED AZOLE DERIVATIVES AS  
THERAPEUTIC AGENTS  
Examiner : Unknown  
Art Unit : 1614  
Atty. Docket : TTP 2002-08

---

Mail Stop: **AMENDMENT**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

Pursuant to 37 C.F.R. § 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08a. One copy of each reference, other than, US Patents or US Patent Publications, is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- ☒ 1. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.
- ☐ 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
- ☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).
- ☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to my

knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56 (c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97 (e) (2).

☐ c. Please debit Deposit Account No. 50-3216 in the amount of \$\_\_\_\_\_ in payment of the fee under 37 C.F.R. § 1.17(p). Two duplicate copies of this paper are attached.


☐ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but on or before payment of the Issue Fee. Applicant(s) hereby petition(s) that the Information Disclosure Statement be considered. Please debit Deposit Account No. 50-3216 in the amount of \$\_\_\_\_\_ in payment of the petition fee under 37 C.F.R. § 1.17 (p). Two duplicate copies of this paper are attached.

☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97 (e) (1).

☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56 (c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97 (e) (2).

Respectfully submitted,

Date: Nov. 30, 2004

  
Samuel B. Rollins  
Registration No. 52,180

TransTech Pharma, Inc.  
4170 Mendenhall Oaks Pkwy  
Suite 110  
High Point, NC 27265  
Phone: (336) 841-0300  
Fax: (336) 841-0310

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**(Use as many sheets as necessary)**

Sheet

of

**Complete if Known**

Application Number	10/777,488
--------------------	------------

<b>Filing Date</b>	02/12/04
--------------------	----------

<b>First Named Inventor</b>	<b>Adnan M.M. Mjalli</b>
-----------------------------	--------------------------

<b>Art Unit</b>	<b>1614</b>
-----------------	-------------

Examiner Name	Unkown
---------------	--------

Attorney Docket Number TTP 2002-08

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	TR-232	WO 97/39748	10/30/97	Andersen et al.		
	TR-233	WO 98/27065	06/25/98	Mjalli et al.		
	TR-230	WO 99/46244	09/16/99	Jeppesen et al.		
	TR-227	WO 02/32897	04/25/02	Day et al.		
	TR-143	WO 02/04412	01/17/02	Burgess et al.		
	TR-144	WO 02/04459	01/17/02	Anderson et al.		
	TR-145	WO 03/020688	03/13/03	Liu et al.		
	TR-146	WO 03/033496	04/24/03	Mjalli et al.		

**Examiner  
Signature**

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.<sup>1</sup> Applicant's unique citation designation number (optional).<sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.<sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

***If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.***

**Complete if Known**

<b>Application Number</b>	10/777,488
<b>Filing Date</b>	02/12/04
<b>First Named Inventor</b>	Adnan M.M. Mjalli
<b>Art Unit</b>	1614
<b>Examiner Name</b>	Unkown
<b>Attorney Docket Number</b>	TTP 2002-08

*(Use as many sheets as necessary)*

Sheet

of

Attorney Docket Number

TTP 2002-08

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> ( <i>if known</i> )				
	TR-147	WO 03/041729	05/22/03	Zhang et al.		
	TR-148	WO 03/048140	06/12/03	Inaba et al.		
	TR-149	WO 03/064376	08/07/03	Swinnen et al.		
	TR-150	WO 03/072537	09/04/03	Szezepankiewicz et al.		
	TR-151	WO 03/073987	09/12/03	Barr et al.		
	TR-152	WO 03/082841	10/09/03	Coppola et al.		
	TR-153	WO 03/092679	11/13/03	Groneberg et al.		
	TR-154	WO 03/093498	11/13/03	Pei et al.		
	TR-156	WO 04/020466	03/11/04	Hoof et al.		

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbol as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

***If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.***

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				<i>Application Number</i>	10/777,488
				<i>Filing Date</i>	02/12/04
				<i>First Named Inventor</i>	Adnan M.M. Mjalli
				<i>Art Unit</i>	1614
				<i>Examiner Name</i>	Unknown
				<i>Attorney Docket Number</i>	TTP 2002-08
Sheet		of			

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	TR-157	WO 04/041799	05/21/04	Birch et al.		
	TR-158	WO 04/050646	06/17/04	Kenny et al.		
	TR-159	WO 04/071447	08/26/04	Mjalli et al.		
	TR-160	WO 04/071448	08/26/04	Mjalli et al.		
	TR-161	WO 04/074238	09/02/04	Gray et al.		
	TR-162	WO 04/074256	09/02/04	Klopfenstein et al.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

***If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.***

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**(Use as many sheets as necessary)**

Sheet

of

**Complete if Known**

Application Number	10/777.488
--------------------	------------

<b>Filing Date</b>	02/12/04
--------------------	----------

First Named Inventor	Adnan M.M. Mialli
----------------------	-------------------

Art Unit	1614
----------	------

Examiner Name	Unknown
---------------	---------

Attorney Docket Number	TTP 2002-08
------------------------	-------------

## U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	TR-131	US- 5,972,978	10/26/1999	Andersen et al.	
	TR-164	US- 6,169,087	01/02/2001	Andersen et al.	
	TR-165	US- 6,174,874	01/16/2001	Wang et al.	
	TR-166	US- 6,214,564	04/10/2001	Rodan et al.	
	TR-167	US- 6,238,902	05/29/2001	Cheng et al.	
	TR-169	US- 6,388,076	05/14/2002	Mjalli et al.	
	TR-170	US- 6,365,592	04/02/2002	Leblanc et al.	
	TR-171	US- 6,410,556	06/25/2002	Andersen et al.	
	TR-172	US- 6,448,429	09/10/2002	Leblanc et al.	
	TR-173	US- 6,465,444	10/15/2002	Bayly et al.	
	TR-174	US- 6,472,545	10/29/2002	Liu et al.	
	TR-175	US- 6,486,141	11/26/2002	Lau et al.	
	TR-176	US- 6,486,142	11/26/2002	Leblanc et al.	
	TR-177	US- 6,498,151	12/24/2002	Li et al.	
	TR-178	US- 6,534,056	03/18/2003	Tromblay et al.	
	TR-179	US- 6,583,126	06/24/2003	Leblanc et al.	
	TR-180	US- 6,586,467	07/01/2003	Burgess et al.	
	TR-181	US- 6,596,772	07/22/2003	Huang et al.	

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.**

EV 507590141 US



Substitute for form 1449A/PTO

*(Use as many sheets as necessary)*

Sheet

of

**Complete if Known**

Application Number	10/777,488
--------------------	------------

<b>Filing Date</b>	02/12/04
--------------------	----------

First Named Inventor	Adnan M.M. Mialli
----------------------	-------------------

Art Unit	1614
----------	------

Examiner Name	Unknown
---------------	---------

Attorney Docket Number	TTP 2002-08
------------------------	-------------

[illegible][illegible]

**Examiner  
Signature**

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.**

EV 507590141 US

Substitute for form 1449A/PTO

**Complete if Known**

*(Use as many sheets as necessary)*

Sheet

of

Application Number

10/777.488

**Filing Date**

02/12/04

**First Named Inventor**

Adnan M.M. Mialli

**Art Unit**

1614

**Examiner Name**

Unknown

Attorney Docket Number

TTP 2002-08

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	TR-190	US- 20020002199	01/03/2002	Jeppesen et al.	
	TR-191	US- 20020009762	01/24/2002	Flint et al.	
	TR-192	US- 20020035137	03/21/2002	Liu et al.	
	TR-193	US- 20020072516	06/13/2002	Liu et al.	
	TR-194	US- 20020099073	07/25/2002	Andersen et al.	
	TR-195	US- 20020138862	09/26/2002	Kennedy et al.	
	TR-196	US- 20020169157	11/14/2002	Liu et al.	
	TR-197	US- 20020183518	12/05/2002	Mjalli et al.	
	TR-198	US- 20030064979	04/03/2003	Hansen et al.	
	TR-199	US- 20030069267	04/10/2003	Moller et al.	
	TR-200	US- 20030108883	06/12/2003	Rondinone et al.	
	TR-201	US- 20030114703	01/19/03	Leblanc et al.	
	TR-202	US- 20030120073	06/26/2003	Seto et al.	
	TR-203	US- 20030144338	07/31/2003	Matsumoto et al.	
	TR-204	US- 20030153756	08/14/2003	Guertin et al.	
	TR-205	US- 20030170660	09/11/2003	Sondergaard et al.	
	TR-206	US- 20030180827	09/25/2003	Weite et al.	
	TR-207	US- 20030130335	07/10/2003	Mjalli et al.	
	TR-208	US- 20030215899	11/20/2003	Meng et al.	
	TR-209	US- 20030217379	11/20/2003	Kennedy et al.	
	TR-210	US-20030194745	10/16/2003	McDowell et al.	

[illegible]

**Examiner  
Signature**

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.**

EV 507590141 US

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**(Use as many sheets as necessary)**

Sheet

of

**Complete if Known**

Application Number	10/777.488
--------------------	------------

<b>Filing Date</b>	02/12/04
--------------------	----------

First Named Inventor	Adnan M.M. Mialli
----------------------	-------------------

Art Unit	1614
----------	------


Examiner Name	Unknown
---------------	---------

Attorney Docket Number	TTP 2002-08
------------------------	-------------

EV 507590141 US

EV 507590141 US

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number



Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

of

**Complete if Known**

Application Number	10/777,488
Filing Date	02/12/04
First Named Inventor	Adnan M.M. Mjalli
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	TTP 2002-08

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	TR-1	ANDERSEN HS, "2-(oxalylamino)-benzoic acid is a general, competitive inhibitor of protein-tyrosine phosphatases." The Journal of Biological Chemistry, 275:7101-7108 (2000)	
	TR-2	MURTHY VS, "3D-QSAR CoMFA and CoMSIA on Protein Tyrosine Phosphatase 1B Inhibitors" Bioorganic & Medicinal Chemistry, 10:2267-2282 (2002)	
	TR-3	MOK A, "A single nucleotide polymorphism in protein tyrosine phosphatase PTP-1B is associated with protection from diabetes or impaired glucose Tolerance in Oji-Cree" The Journal of Clinical Endocrinology & Metabolism, 87(2): 724-727 (2002)	
	TR-4	SHEN K, "Acquisition of a specific and potent PTP1B inhibitor from a novel combinatorial library and screening procedure." The Journal of Biological Chemistry, 276:47311-47319 (2001)	
	TR-5	COVIC L, "Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides." Proceedings of the National Academy of Sciences, 99:643-648 (2002)	
	TR-6	LIU DG, "Acylsulfonamide-containing PTP1B inhibitors designed to mimic an enzyme-bound water of hydration." Bioorganic & Medicinal Chemistry Letters, 13:3005-3007 (2003)	
	TR-7	WIESMANN C, "Allosteric inhibition of protein tyrosine phosphatase 1B" Nature Structural & Molecular Biology, 11:730-737 (2004)	
	TR-8	LI X, "Alpha, alpha-difluoro-beta-ketophosphonates as potent inhibitors of protein tyrosine phosphatase 1B." Bioorganic & Medicinal Chemistry Letters, 14:4301-4306 (2004)	
	TR-9	ARABACI G, "alpha-bromoacetophenone derivatives as neutral protein tyrosine phosphatase inhibitors: structure-Activity relationship." Bioorganic & Medicinal Chemistry Letters, 12:3047-3050 (2002)	
	TR-10	CHO KJ, "Alpha-lipoic acid decreases thiol reactivity of the insulin receptor and protein tyrosine phosphatase 1B in 3T3-L1 adipocytes." Biochemical Pharmacology, 66:849-858 (2003)	
	TR-11	AHMAD F, "Alterations in skeletal muscle protein-tyrosine phosphatase activity and expression in insulin-resistant human obesity and diabetes." Journal of Clinical Investigation, 100:449-458 (1997)	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 507590141 US

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

of

**Complete if Known**

Application Number	10/777,488
Filing Date	02/12/04
First Named Inventor	Adnan M.M. Mjalli
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	TTP 2002-08

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	TR-12	WANG WQ, "An overview of the protein tyrosine phosphatase superfamily." Current Topics in Medicinal Chemistry, 3:739-748 (2003)	
	TR-13	GUM RJ, "Antisense Protein Tyrosine Phosphatase 1B Reverses Activation of p38 Mitogen-Activated Protein Kinase in Liver of ob/ob Mice." Molecular Endocrinology, 17:1131-1143 (2003)	
	TR-14	VETTER SW, "Assessment of protein-tyrosine phosphatase 1B substrate specificity using "inverse alanine scanning"." The Journal of Biological Chemistry, 275:2265-2268 (2000)	
	TR-15	PATANI G. "Bioisosterism: A Rational Approach in Drug Design." Chemical Review, 96, 3147-3176 (1996)	
	TR-16	LEE K, "CD45 protein-tyrosine phosphatase inhibitor development." Current Topics in Medicinal Chemistry, 3:797-807 (2003)	
	TR-17	IRIE-SASAKI J, "CD45 regulated signaling pathways." Current Topics in Medicinal Chemistry, 3:783-996 (2003)	
	TR-18	CHU W, "Cell-free Synthesis of Preparative Amounts of Enzymatically Active Human PTP1B" Biochemica, 2:28-29 (2001)	
	TR-19	XIE L, "Cellular effects of small molecule PTP1B inhibitors on insulin signaling." Biochemistry, 42:12792-12804 (2003)	
	TR-20	TAYLOR WP, "Charged with meaning: the structure and mechanism of phosphoprotein phosphatases." Chemistry & Biology, 2:713-718 (1995)	
	TR-21	PATANKAR SJ, "Classification of Inhibitors of Protein Tyrosine Phosphatase 1B Using Molecular Structure Based Descriptors " Journal of Chemical Information and Computer Sciences, 43:885-899 (2003)	
	TR-22	SUN JP, "Crystal structure of PTP1B complexed with a potent and selective bidentate inhibitor." The Journal of Biological Chemistry, 278:12406-12414 (2003)	
	TR-223	DATABASE CAPLUS "Online! Chemical Abstracts Service, Columbus, Ohio, US; HOSHINO, KAZUKI et al: "Anti-infective agents and drug efflux pump inhibitors containing heteroaromatic compounds and" retrieved from STN Database accession no. 2002: 849289 RN 3347904-05-9, RN 337903-96-5, abstract & JP 2002 322054, Japan; 8 November 2002	
	TR-24	YAN Z, "Design and synthesis of phosphotyrosine mimetics." Bioorganic & Medicinal Chemistry Letters, 13:2083-2085 (2003)	

Examiner  
SignatureDate  
Considered


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 507590141 US



PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

of

**Complete if Known**

Application Number	10/777,488
Filing Date	02/12/04
First Named Inventor	Adnan M.M. Mjalli
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	TTP 2002-08

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	TR-25	ANDERSEN HS, "Discovery and SAR of a novel selective and orally bioavailable nonpeptide classical competitive inhibitor class of protein-tyrosine phosphatase 1B." Journal of Medicinal Chemistry, 45:4443-4459 (2002)	
	TR-26	PEI Z, "Discovery and SAR of novel, potent and selective protein tyrosine phosphatase 1B inhibitors." Bioorganic & Medicinal Chemistry Letters, 13:3129-3132 (2003)	
	TR-27	LIU G, "Discovery and structure-activity relationship of oxalylarylaminobenzoic acids as inhibitors of protein tyrosine phosphatase 1B." Journal of Medicinal Chemistry, 46:2093-2103 (2003)	
	TR-28	ERLANSON DA, "Discovery of a New Phosphotyrosine Mimetic for PTP1B Using Breakaway Tethering" Journal of the American Chemical Society, 125:5602-5603 (2003)	
	TR-29	HYAE GYEONG CHEON, "Discovery of a novel protein tyrosine phosphatase-1B inhibitor, KR61639: potential development as an antihyperglycemic agent" European Journal of Pharmacology, 485:333-339 (2004)	
	TR-30	OCKEY DA, "Discovery of novel PTP1b inhibitors " Bioorganic & Medicinal Chemistry Letters, 14:389-391 (2004)	
	TR-31	CHEN YT, "Divalent and trivalent alpha-ketocarboxylic acids as inhibitors of protein tyrosine phosphatases." Journal of Medicinal Chemistry, 45:3946-3952 (2002)	
	TR-32	BOUTE N, "Dynamics of the interaction between the insulin receptor and protein tyrosine-phosphatase 1B in living cells." EMBO Reports, 4:313-319 (2003)	
	TR-33	PETRONE A, "Emerging issues in receptor protein tyrosine phosphatase function: lifting fog or simply shifting?" Journal of Cell Science, 113:2345-2354 (2000)	
	TR-34	PETERS GH, "Enzyme kinetic characterization of protein tyrosine phosphatases" Biochimie, 85:527-534 (2003)	
	TR-35	SHRESTHA S, "Evans Blue and other dyes as protein tyrosine phosphatase inhibitors." Bioorganic & Medicinal Chemistry Letters, 14:1923-1926 (2004)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 507590141 US



Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

of

**Complete if Known**

Application Number 10/777,488

Filing Date 02/12/04

First Named Inventor Adnan M.M. Mjalli

Art Unit 1614

Examiner Name Unknown

Attorney Docket Number TTP 2002-08

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	TR-36	CROSS KP, "Finding discriminating structural features by reassembling common building blocks." Journal of Medicinal Chemistry, 46:4770-4775 (2003)	
	TR-37	WANG Q, "Fluorescein monophosphates as fluorogenic substrates for protein tyrosine phosphatases." Biochimica Et Biophysica Acta, 1431:14-23 (1999)	
	TR-38	SHIM YS, "Formylchromone derivatives as a novel class of protein tyrosine phosphatase 1B inhibitors." Bioorganic & Medicinal Chemistry Letters, 13:2561-2563 (2003)	
	TR-39	LIU G, "Fragment screening and assembly: a highly efficient approach to a selective and cell active protein tyrosine phosphatase 1B inhibitor." Journal of Medicinal Chemistry, 46:4232-4235 (2003)	
	TR-40	ROMSICKI Y, "Functional characterization and crystal structure of the C215D mutant of protein-tyrosine phosphatase-1B." The Journal of Biological Chemistry, 278:29009-15 (2003)	
	TR-41	PHAN J, "High-Resolution Structure of the Yersinia pestis Protein Tyrosine Phosphatase YopH in Complex with a Phosphotyrosyl Mimetic-Containing Hexapeptide." Biochemistry, 42:13113-13121 (2003)	
	TR-42	XIN Z, "Identification of a monoacid-Based, cell permeable, selective inhibitor of protein tyrosine phosphatase 1B " Bioorganic & Medicinal Chemistry Letters, 13:3947-3950 (2003)	
	TR-43	PUIUS YA, "Identification of a second aryl phosphate-binding site in protein-tyrosine phosphatase 1B: a paradigm for inhibitor design." Proceedings of the National Academy of Sciences, 94:13420-13425 (1997)	
	TR-44	FUKADA T, "Identification of YB-1 as a regulator of PTP1B expression: implications for regulation of insulin and cytokine signaling." The EMBO Journal, 22:479-493 (2003)	
	TR-45	ELCHEBLY M, "Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene." Science, 283:1544-1548 (1999)	
	TR-46	ZABELL AP, "Inhibition studies with rationally designed inhibitors of the human low molecular weight protein tyrosine phosphatase." Bioorganic & Medicinal Chemistry, 12:1867-1880 (2004)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 507590141 US





PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

of

**Complete if Known**

Application Number	10/777,421
Filing Date	02/04/04
First Named Inventor	Adnan M.M. Mjalli
Art Unit	1615
Examiner Name	Unknown
Attorney Docket Number	TTP 2002-07

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	TR-59	DOMAN TN, "Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B." Journal of Medicinal Chemistry, 45:2213-2221 (2002)	
	TR-60	PETERS GH, "Molecular dynamics simulations of protein-tyrosine phosphatase 1B. I. ligand-induced changes in the protein motions." Biophysical Journal, 77:505-515 (1999)	
	TR-61	PETERS GH, "Molecular dynamics simulations of protein-tyrosine phosphatase 1B. II. substrate-enzyme interactions and dynamics." Biophysical Journal, 78:2191-2200 (2000)	
	TR-62	MALAMAS MS, "New azolidinediones as inhibitors of protein tyrosine phosphatase 1B with antihyperglycemic properties." Journal of Medicinal Chemistry, 43:995-1010 (2000)	
	TR-63	MALAMAS MS, "Novel benzofuran and benzothiophene biphenyls as inhibitors of protein tyrosine phosphatase 1B with antihyperglycemic properties." Journal of Medicinal Chemistry, 43:1293-1310 (2000)	
	TR-234	MEANWELL et al., "Nonprostanoid Prostaqcyclin Mimetics. 2. 4,5-Diphenyloxazole Derivatives", Journal of Medicinal Chemistry, Vol. 35, pages 3483-3497 (1992)	
	TR-64	GLOVER NR, "Nuclear magnetic resonance and restrained molecular dynamics studies of the interaction of an epidermal growth factor-derived peptide with protein tyrosine phosphatase 1B." Biochemistry, 38:5256-5271 (1999)	
	TR-65	LILJEBRIS C, "Oxidation of protein tyrosine phosphatases as a pharmaceutical mechanism of action: a study using 4-hydroxy-3,3-dimethyl-2H-benzo[g]indole-2,5(3H)-dione." The Journal of Pharmacology & Experimental Therapeutics, 309:711-719 (2004)	
	TR-66	VAN MONTFORT RL, "Oxidation state of the active-site cysteine in protein tyrosine phosphatase 1B." Nature, 423:773-777 (2003)	
	TR-67	CHEN YT, "Parallel synthesis of a library of bidentate protein tyrosine phosphatase inhibitors based on the alpha-ketoacid motif." Bioorganic & Medicinal Chemistry, 12:3289-3298 (2004)	
	TR-68	CHEN YT, "Peptidic alpha-Ketocarboxylic Acids and Sulfonamides as Inhibitors of Protein Tyrosine Phosphatases." Journal of Organic Chemistry, 68:4123-4125 (2003)	
	TR-69	TAING M, "Potent and highly selective inhibitors of the protein tyrosine phosphatase 1B" Biochemistry, 38:3793-3803 (1999)	

Examiner  
SignatureDate  
Considered


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 507590141 US



PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet \_\_\_\_\_ of \_\_\_\_\_

**Complete if Known**

Application Number	10/777,488
Filing Date	02/12/04
First Named Inventor	Adnan M.M. Mjalli
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	TTP 2002-08

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	TR-70	URBANEK, "Potent Reversible Inhibitors of the Protein Tyrosien Phosphatase CD45" Journal of Medical Chemistry, 44: 1777-1793 (2001)	
	TR-71	XIN Z, "Potent, selective inhibitors of protein tyrosine phosphatase 1B." Bioorganic & Medicinal Chemistry Letters, 13:1887-1890 (2003)	
	TR-72	GUO XL, "Probing the molecular basis for potent and selective protein-tyrosine phosphatase 1B inhibition." The Journal of Biological Chemistry, 277:41014-41022 (2002)	
	TR-73	HOOFT VAN HUIJSDUIJNEN R, "Prospects for inhibitors of protein tyrosine phosphatase 1B as antidiabetic drugs." Journal of Medicinal Chemistry, 47:4142-4146 (2004)	
	TR-74	LIU G, "Protein tyrosine phosphatase 1B inhibition: opportunities and challenges." Current Medicinal Chemistry, 10:1407-1421 (2003)	
	TR-75	JOHNSON TO, "Protein tyrosine phosphatase 1B inhibitors for diabetes" Nature Reviews Drug Discovery, 1:696-709 (2002)	
	TR-76	RONDINONE CM, "Protein tyrosine phosphatase 1B reduction regulates adiposity and expression of genes involved in lipogenesis." Diabetes, 51:2405-2411 (2002)	
	TR-77	RAMACHANDRAN C, "Protein tyrosine phosphatase 1B: a novel target for type 2 diabetes and obesity." Current Topics in Medicinal Chemistry, 3:749-757 (2003)	
	TR-78	ROMSICKI Y, "Protein Tyrosine Phosphatase-1B Dephosphorylation of the Insulin Receptor Occurs in a Perinuclear Endosome Compartment in Human Embryonic Kidney 293 Cells." The Journal of Biological Chemistry, 279:12868-12875 (2004)	
	TR-79	WU ZL, "Protein tyrosine phosphatases are up-regulated and participate in cell death induced by polyglutamine expansion." The Journal of Biological Chemistry, 277:44208-44213 (2002)	
	TR-80	ALONSO A, "Protein tyrosine phosphatases in the human genome." Cell, 117:699-711 (2004)	
	TR-81	ZHANG ZY, "PROTEIN TYROSINE PHOSPHATASES: Structure and Function, Substrate Specificity, and Inhibitor Development" Annual Review of Pharmacology and Toxicology, 42:209-234 (2002)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 507590141 US



PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

of

**Complete if Known**

Application Number 10/777,488

Filing Date 02/12/04

First Named Inventor Adnan M.M. Mjalli

Art Unit 1614

Examiner Name Unknown

Attorney Docket Number TTP 2002-08

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	TR-82	GOLDSTEIN BJ, "Protein-tyrosine phosphatase 1B (PTP1B): a novel therapeutic target for type 2 diabetes mellitus, obesity and related states of insulin resistance." Current Drug Targets - Immune, Endocrine & Metabolic Disorders, 1:265-275 (2001)	
	TR-83	DADKE S; CHERNOFF J, "Protein-Tyrosine Phosphatase 1B as a Potential Drug Target for Obesity" Current Drug Targets - Immune, Endocrine & Metabolic Disorders, 3:299-304 (2003)	
	TR-84	SHIMIZU S, "Protein-tyrosine Phosphatase 1B as New Activator for Hepatic Lipogenesis via Sterol Regulatory Element-binding Protein-1 Gene Expression." The Journal of Biological Chemistry, 278:43095-43101 (2003)	
	TR-85	DADKE S, "Protein-tyrosine phosphatase 1B mediates the effects of insulin on the actin cytoskeleton in immortalized fibroblasts." The Journal of Biological Chemistry, 278:40607-40611 (2003)	
	TR-86	GOLDSTEIN BJ, "Protein-tyrosine phosphatases: emerging targets for therapeutic intervention in type 2 diabetes and related states of insulin resistance" The Journal of Clinical Endocrinology & Metabolism, 87:2474-2480 (2002)	
	TR-88	ZINKER BA, "PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice." Proceedings of the National Academy of Sciences, 99:11357-11362 (2002)	
	TR-89	WARING JF, "PTP1B antisense-treated mice show regulation of genes involved in lipogenesis in liver and fat." Molecular and Cellular Endocrinology, 203:155-168 (2003)	
	TR-90	TONKS NK, "PTP1B: from the sidelines to the front lines" FEBS Letters, 546:140-148 (2003)	
	TR-91	ROMSICKI Y, "Purification and characterization of T cell protein tyrosine phosphatase reveals significant functional homology to protein tyrosine phosphatase-1B." Archives of Biochemistry and Biophysics, 414:40-50 (2003)	
	TR-92	SALMEEN A, "Redox regulation of protein tyrosine phosphatase 1B involves a sulphenyl-amide intermediate." Nature, 423:769-773 (2003)	
	TR-93	GUM RJ, "Reduction of protein tyrosine phosphatase 1B increases insulin-dependent signaling in ob/ob mice." Diabetes, 52:21-28 (2003)	


Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 507590141 US



PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

of

**Complete if Known**

Application Number	10/777,488
Filing Date	02/12/04
First Named Inventor	Adnan M.M. Mjalli
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	TTP 2002-08

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	TR-94	GALIC S, "Regulation of insulin receptor signaling by the protein tyrosine phosphatase TCPTP." Molecular And Cellular Biology, 23:2096-2108 (2003)	
	TR-95	HAI FG, "Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatase-1B." The Journal of Biological Chemistry, 278:739-44 (2003)	
	TR-96	PETERS GH, "Residue 259 is a key determinant of substrate specificity of protein-tyrosine phosphatases 1B and alpha." The Journal of Biological Chemistry, 275:18201-18209 (2000)	
	TR-97	LIU G, "Selective protein tyrosine phosphatase 1B inhibitors: targeting the second phosphotyrosine binding site with non-carboxylic acid-containing ligands." Journal of Medicinal Chemistry, 46:3437-3440 (2003)	
	TR-98	MILARSKI KL, "Sequence specificity in recognition of the epidermal growth factor receptor by protein tyrosine phosphatase 1B." The Journal of Biological Chemistry, 268:23634-23639 (1993)	
	TR-99	HALAZY S, "Signal Transduction: An Exciting Field of Investigation for Small Molecule Drug Discovery" Molecules, 8:349-358 (2003)	
	TR-100	BLEASDALE JE, "Small molecule peptidomimetics containing a novel phosphotyrosine bioisostere inhibit protein tyrosine phosphatase 1B and augment insulin action." Biochemistry, 40:5642-5654 (2001)	
	TR-229	CESCON GR, "Some Properties of Triarylimidazolyl Radicals and Their Dimers" Journal of Organic Chemistry, Vol. 36, No. 16, (1971)	
	TR-101	XIE J, "Squaric Acids: A New Motif for Designing Inhibitors of Protein Tyrosine Phosphatases " Organic Letters, 6:83-86 (2004)	
	TR-102	DILLET V, "Stabilization of Charges and Protonation States in the Active Site of the Protein Tyrosine Phosphatases: A Computational Study" Journal of Physical Chemistry B, 104:11321-11333 (2000)	
	TR-103	IVERSEN LF, "Steric hindrance as a basis for structure-based design of selective inhibitors of protein-tyrosine phosphatases." Biochemistry, 40:14812-14820 (2001)	
	TR-104	ANDERSEN JN, "Structural and evolutionary relationships among protein tyrosine phosphatase domains." Molecular And Cellular Biology, 21:7117-7136 (2001)	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 507590141 US



PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/777,488
Filing Date	02/12/04
First Named Inventor	Adnan M.M. Mjalli
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	TTP 2002-08

Sheet

of

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	TR-105	GROVES M, "Structural Basis for Inhibition of the Protein Tyrosine Phosphatase 1B by Phosphotyrosine Peptide Mimetics" Biochemistry, 37:17773-17783 (1998)	
	TR-106	SARMIENTO M, "Structural basis of plasticity in protein tyrosine phosphatase 1B substrate recognition" Biochemistry, 39:8171-8179 (2000)	
	TR-107	LAU C, "Structure based design of a series of potent and selective non peptidic PTP-1B inhibitors" Bioorganic & Medicinal Chem. Letters, 14: 1043-4048 (2004)	
	TR-108	VERSEN LF, "Structure determination of T cell protein-tyrosine phosphatase." The Journal of Biological Chemistry, 277:19982-19990 (2002)	
	TR-109	JIA Z, "Structure of protein tyrosine phosphatase 1B in complex with inhibitors bearing two phosphotyrosine mimetics." Journal of Medicinal Chemistry, 44:4584-4594 (2001)	
	TR-110	IVERSEN LF, "Structure-based design of a low molecular weight, nonphosphorus, nonpeptide, and highly selective inhibitor of protein-tyrosine phosphatase 1B." The Journal of Biological Chemistry, 275:10300-10307 (2000)	
	TR-111	LUND IK, "Structure-based design of selective and potent inhibitors of protein-tyrosine phosphatase beta." The Journal of Biological Chemistry, 279:24226-24235 (2004)	
	TR-112	SARMIENTO M, "Structure-based discovery of small molecule inhibitors targeted to protein tyrosine phosphatase 1B." Journal of Medicinal Chemistry, 43:146-155 (2000)	
	TR-113	WANG J, "Structure-based Prediction of Free Energy Changes of binding of PTP1B Inhibitors" Journal of Computer-Aided Molecular Design, 17:495-513 (2003)	
	TR-114	MCCAIN DF, "Suramin derivatives as inhibitors and activators of protein-tyrosine phosphatases." The Journal of Biological Chemistry, 279:14713-14725 (2004)	
	TR-115	LILJEBRIS C, "Synthesis and biological activity of a novel class of pyridazine analogues as non-competitive reversible inhibitors of protein tyrosine phosphatase 1B (PTP1B)." Bioorganic & Medicinal Chemistry, 10:3197-3212 (2002)	
	TR-116	LARSEN SD, "Synthesis and biological activity of a novel class of small molecular weight peptidomimetic competitive inhibitors of protein tyrosine phosphatase 1B" Journal of Medicinal Chemistry, 45:598-622 (2002)	
	TR-117	THERIEN M, "Synthesis of a novel peptidic photoaffinity probe for the PTP-1B enzyme." Bioorganic & Medicinal Chemistry Letters, 14:2319-2322 (2004)	


Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 507590141 US



PTO/SB/08b(08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
		<b>Application Number</b>	10/777,488
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Filing Date</b>	02/12/04
		<b>First (Named) Inventor</b>	Adnan M.M. Mjalli
		<b>Art Unit</b>	1614
		<b>Examiner Name</b>	Unknown
		<b>Attorney Docket Number</b>	TTP 2002-08
Sheet		of	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	TR-118	DUFRESNE C, "The development of potent non-peptidic PTP-1B inhibitors." Bioorganic & Medicinal Chemistry Letters, 14:1039-1042 (2004)	
	TR-119	LEUNG C, "The difluoromethylenesulfonic acid group as a monoanionic phosphate surrogate for obtaining PTP1B inhibitors." Bioorganic & Medicinal Chemistry, 10:2309-2323 (2002)	
	TR-120	MOONEY RA, "The leukocyte common antigen-related protein LAR: candidate PTP for inhibitory targeting." Current Topics in Medicinal Chemistry, 3:809-819 (2003)	
	TR-122	TIGANIS T, "The protein-tyrosine phosphatase TCPTP regulates epidermal growth factor receptor-mediated and phosphatidylinositol 3-kinase-dependent signaling." The Journal of Biological Chemistry, 274:27768-27775 (1999)	
	TR-123	WIDLANSKI TS, "The road less travelled: taming phosphatases." Chemistry & Biology, 4:489-492 (1997)	
	TR-124	DUBE N, "The role of protein tyrosine phosphatase 1B in Ras signaling." Proceedings of the National Academy of Sciences, 101:1834-1839 (2004)	
	TR-125	ESPANEL X, "The SPOT technique as a tool for studying protein tyrosine phosphatase substrate specificities." Protein Science, 11:2326-2334 (2002)	
	TR-126	SCAPIN G, "The structural basis for the selectivity of benzotriazole inhibitors of PTP1B." Biochemistry, 42:11451-11459 (2003)	
	TR-127	ASANTE-APPIAH E, "The structure of PTP-1B in complex with a peptide inhibitor reveals an alternative binding mode for bisphosphonates." Biochemistry, 41:9043-9051 (2002)	
	TR-128	BUKCYNSKA P, "The T-cell protein tyrosine phosphatase is phosphorylated on Ser-304 by cyclin-dependent protein kinases in mitosis." Biochemical Journal, 380:939-949 (2004)	
	TR-129	RAGAB A, "The tyrosine phosphatase 1B regulates linker for activation of T-cell phosphorylation and platelet aggregation upon FcgammaRIIa cross-linking." The Journal of Biological Chemistry, 278:40923-40932 (2003)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 507590141 US



PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/777,488
Filing Date	02/12/04
First Named Inventor	Adnan M.M. Mjalli
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	TTP 2002-08

Sheet

of

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	TR-130	ZABOLOTNY JM, "Transgenic Overexpression of Protein-tyrosine Phosphatase 1B in Muscle Causes Insulin Resistance, but Overexpression with Leukocyte Antigen-related Phosphatase Does Not Additively Impair Insulin Action." The Journal of Biological Chemistry, 279:24844-24851 (2004)	
	TR-131	LEE K, "Tripeptide inhibitors of Yersinia protein-tyrosine phosphatase." Bioorganic & Medicinal Chemistry Letters, 13:2577-2581 (2003)	
	TR-132	SIMS C, "Tyrosine phosphatase inhibitors selectively antagonize beta-adrenergic receptor-dependent regulation of cardiac ion channels." Molecular Pharmacology, 58:1213-1221 (2000)	
	TR-133	ZHU L, "Use of an Anaerobic Chamber Environment for the Assay of Endogenous Cellular Protein-Tyrosine Phosphatase Activities." Biological Procedures Online, 4:1-9 (2002)	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 507590141 US